This week, the S&P Global Market Intelligence Healthcare news team presents a weeklong series focusing on Alzheimer's disease. Our reporters examined the current state of research on the debilitating neurological disease and the state of the drug pipeline in this series, Alzheimer's in Focus.
Once considered failures, some Alzheimer's drugs get 2nd chance in new trials
A promising type of Alzheimer's disease therapy that tackles a buildup of proteins called beta-amyloid in the brain has failed over and over in the clinic, but researchers are nevertheless continuing to tinker with these drug candidates to see if they can provide any pharmaceutical benefit whatsoever — perhaps at earlier stages of the disease.
Q&A: Academic at UK Dementia Research Institute talks Alzheimer's today
Giovanna Lalli, head of scientific affairs at the U.K. Dementia Research Institute at University College London, spoke to S&P Global Market Intelligence about the current state of play in the Alzheimer's market.
Ionis, Biogen leverage RNA-driven drugs to target Alzheimer's disease marker
Ionis Pharmaceuticals Inc., partnered with well-known Alzheimer's drug developer Biogen Inc., is using its antisense oligonucleotide platform to target Alzheimer's disease.
World's No. 1 killer provides model for tackling surge in Alzheimer's cases
The approach to tackling heart disease holds lessons for addressing the rising specter of Alzheimer's disease, experts say.
Biohaven seeks to fill gap in treatment of Alzheimer's symptoms with troriluzole
Many researchers in the Alzheimer's disease space are focused on developing treatments to slow or reverse the condition, but Biohaven Pharmaceutical Holding Co. Ltd. is looking to fill the gap in therapies for existing symptoms with its drug candidate troriluzole.
Failures in Alzheimer's research spur new approaches to drug development
The Alzheimer's disease drug pipeline is riddled with failures, but pharma companies are vying for what would be a massive reward, as an estimated 74.7 million individuals worldwide will develop the disorder by 2030.Chart of the Week
Story: J&J, Ascletis among drugmakers racing to unlock China's hepatitis B market
'Fight like hell': Medicaid expansion debates define 2019 legislative sessions
After Medicaid expansion had a moment in the national spotlight during the 2018 midterm elections, the fight over implementing expansion plans has continued at the state level, defining the 2019 state legislative sessions.
AstraZeneca's Symbicort cuts mild asthma attacks by 51% in new study
AstraZeneca PLC's Symbicort reduced the number of annual asthma attacks by 51% compared to salbutamol in a study that suggests the inhaled medicine could also potentially be used to treat mild asthma.
Zai Lab CEO and Chairman Samantha Du
Zai Lab CEO discusses drug development, cancer drug Zejula's prospects
The Shanghai-based company has over 200 employees working in research and development, and there are plans to lift that number by 50%, said CEO Samantha Du.
Merck & Co.'s $1.05B Peloton deal signals cancer trajectory beyond Keytruda
Dallas-based Peloton Therapeutics Inc.'s specialty is one familiar to Merck & Co. Inc. — a focus on renal cell carcinoma — where Keytruda and Pfizer Inc.'s Inlyta scored a key U.S. Food and Drug Administration approval in April.
Execs debate responsibilities of innovation, facing changes to the health sector
At a forum in New York, executives from various parts of the healthcare sector debated issues including gene-editing concerns and the changes the industry is facing if certain legislative proposals are adopted.
Essential Healthcare is a weekly collection of critical developments across the pharmaceutical, biotechnology, healthcare provider, healthcare technology and medical equipment industries that draws on exclusive analysis and value-added content from the Healthcare News team at S&P Global Market Intelligence. Subscribe now to get Essential Healthcare delivered to your inbox every week.